CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2017—GenomeDx Biosciences and Pathnostics announced a strategic agreement for GenomeDx to distribute Pathnostics’ Guidance UGx for urinary tract infections and Guidance PRx for prostatitis. These molecular diagnostic tests detect the genomic sequence of pathogens, providing a faster and more comprehensive solution for physicians and their patients.
GenomeDx will have exclusive distribution rights for Guidance UGx and Guidance PRx in most of the U.S. urology market, and Pathnostics will perform the testing at its CAP-accredited, CLIA-certified laboratory in Irvine, Calif.
GenomeDx, 888-975-4540
Pathnostics, 714-966-1221